Increased COX-2 Immunostaining in Urothelial Carcinoma of the Urinary Bladder Is Associated with Invasiveness and Poor Prognosis

Basim Al-Maghrabi,1 Wafaey Gomaa,2,3 Mohammed Abdelwahed,4,5 and Jaudah Al-Maghrabi1,2,6

1Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
2Department of Pathology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
3Department of Pathology, Faculty of Medicine, Minia University, Al-Minia, Egypt
4Department of Pathology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
5Department of Pathology, Faculty of Medicine, University of Jeddah, Jeddah, Saudi Arabia
6Department of Pathology, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia

Correspondence should be addressed to Jaudah Al-Maghrabi; jalmaghrabi@hotmail.com

Received 11 August 2018; Accepted 31 March 2019; Published 21 April 2019

Academic Editor: Elena Adinolfi

Copyright © 2019 Basim Al-Maghrabi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Urothelial carcinoma of the urinary bladder (UCB) is the commonest bladder tumor. Cyclooxygenase-2 (COX-2) mediates angiogenesis, cell survival/proliferation, and apoptosis. This study investigates the relation of COX-2 immunostaining in UCB to clinicopathological parameters in Saudi Arabia.

Methods. The study population includes 123 UCB and 25 urothelial mucosae adjacent to UCB. UCB samples were collected before any local or systemic therapy. Tissue microarrays were designed and constructed, and TMA blocks were sliced for further immunohistochemical staining. Immunohistochemical staining was done using a mouse anti-human COX-2 monoclonal antibody. A cutoff point of 10% was chosen as the threshold to determine low and high COX-2 immunostaining.

Results. COX-2 immunostaining is higher in UCB than in the adjacent urothelium (p=0.033). High COX-2 immunostaining is associated with high-grade UCB (p=0.013), distant metastasis (p=0.031), lymphovascular invasion (p=0.008), positive muscle invasion (p=0.017), pT2 and above (p=0.003), and high anatomical stages (stage II and above). High COX-2 immunostaining is higher in UCB than in the adjacent urothelium (p=0.033). High COX-2 immunostaining is associated with high-grade UCB (p=0.013), distant metastasis (p=0.031), lymphovascular invasion (p=0.008), positive muscle invasion (p=0.017), pT2 and above (p=0.003), and high anatomical stages (stage II and above). High COX-2 immunostaining is an independent predictor of higher tumor grade (p<0.001), muscle invasion (p=0.015), advanced pathological T (p=0.014), lymphovascular invasion (p=0.011), and distant metastasis (p=0.039). High COX-2 immunostaining is associated with lower overall survival rate (p=0.019). Conclusion. COX-2 immunostaining is associated with the invasiveness of UCB which may be used as an independent prognostic marker. COX-2 may be a significant molecule in the initiation and progression of UCB. Molecular and clinical investigations are required to explore the molecular downstream of COX-2 in UCB and effectiveness of COX-2 inhibitors as adjuvant therapy along with traditional chemotherapy.

1. Background

Urothelial carcinoma of the urinary bladder (UCB) is the commonest bladder tumor in Western countries [1]. In Saudi Arabia, UCB represents 3.8% of cancers in males [2]. UCB predominantly manifests as a non-muscle-invasive tumor. Low-grade tumors have a good prognosis after transurethral resection while patients with high-grade tumors require intravesical instillation of Bacillus Calmette-Guerin and/or chemotherapy. In 70% of non-muscle-invasive UCB, patients suffer a recurrence following treatment. In 15% of noninvasive UCB, muscle invasion develops. Progression risk is
potential in patients with high-grade tumors [3]. The cost of therapy is still high because of the high risk of recurrence and the close lifetime follow-up [4].

Chronic inflammation is thought to increase the risk of UCB [5]. Cyclooxygenase-2 (COX-2) is a prostaglandin endoperoxide synthetase. Proinflammatory cytokines, growth factors, tumor initiators, and other external factors stimulate COX-2 to catalyse prostanoid production [6, 7]. Activation of COX-2 facilitates cellular processes and is involved in tumorigenesis such as angiogenesis, tumor cell proliferation, survival, and apoptosis [8, 9]. Urinary bladder tissue in patients with cystitis or UCB showed increased COX-2 levels as compared to normal urinary bladder tissue [10, 11]. COX-2 is overexpressed in UCB [11–14] and colorectal carcinoma [15].

The objective of this study is to investigate the relation of the COX-2 immunostaining status to various clinicopathological parameters and its value as a predictor of disease outcome in a subset of UCB patients from Saudi Arabia. Up to our knowledge, this is the first study to address this relation in Saudi Arabian UCB patients.

2. Methods

2.1. Patients. A total of 123 UCB and 25 uninvolved nearby urothelial mucosae adjacent to UCB are included in the current study. All pathological materials were recruited in the Department of Pathology, King Abdulaziz University, Jeddah, Saudi Arabia. UCB samples used in the study were obtained before any intravesical or systemic therapy. Tumors were reviewed regarding the T stage according to the criteria of the Cancer Staging Atlas of the American Joint Committee on Cancer [16], while the grade was revised according to the World Health Organization classification of tumors [17]. The clinicopathological findings are shown in Table 1. The Research Committee of the Biomedical Ethics Unit, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, approved this study. Informed written consents to use their biopsy material in research were obtained from patients included in this study.

2.2. Tissue Microarray. The design and construction of tissue microarrays were performed as previously described [18, 19]. Two cores of tissue were selected from each UCB and uninvolved urothelial mucosa and arrayed in recipient paraffin blocks. The automated tissue arrayer (Master 3DHISTECH) was used. Normal placenta tissues were used for orientation of cores in TMA blocks. TMA blocks were sliced into 4-micrometer sections and mounted on positive-charged slides for further immunohistochemical staining.

2.3. Immunohistochemistry. Immunohistochemical staining was done using a mouse anti-human COX-2 monoclonal antibody (DakoCytomation Norden A/S, Glostrup, Denmark; dilution 1:50). The immunostaining procedure was carried out using an automatic immunostainer (Ventana BenchMark XT, Ventana Inc., Tucson, AZ). Positive controls were used consisting of colorectal carcinomas known to be positive for an anti-COX-2 antibody. Negative controls were treated with tris-buffered saline instead of primary antibody.

2.4. Evaluation of COX-2 Immunostaining. A semiquantitative scoring was used by recording the percentage of positive cells for COX-2. In each disk of tissue, the tumor/urothelial cells were counted, and subsequently, the positive cells (cytoplasmic brown staining) were counted. The percentage of COX-2-positive cells was calculated. A cutoff point of 10% was chosen as the threshold. COX-2-negative immunostaining was assigned when less than 10% of the examined tumor/urothelial cells were stained while COX-2-positive immunostaining was considered when equal to or greater than 10% of the examined tumor/urothelial cells were stained 20–23. Accordingly, we classified COX-2 immunostaining into high and low immunostaining.

2.5. Statistical Analysis. Statistical tests were performed in the SPSS® program (NY, USA) version 16. The statistical
significance was considered at \( p < 0.05 \). Testing the difference between two and three variables was calculated by using the Mann-Whitney \( U \) test, and Kruskal-Wallis tests were used alternatively. Along one variable of data, the variation was tested using the nonparametric chi-squared test. The Kaplan-Meier method with the log-rank (Mantel-Cox) test was used to compare the survival probability. Disease-free survival was calculated as the time from diagnosis to the appearance of recurrent disease (or the date last seen being disease free). Binary logistic regression analysis was utilised to determine the prognostic value of COX-2 immunostaining. The estimated odds ratio (exponential(\( B \)) and 95% confidence interval for \( \exp [B] \) were expressed.

### 3. Results

#### 3.1. Pattern of COX-2 Immunostaining

The staining pattern of COX-2 in UCB and the adjacent urothelium is shown in Figure 1. In the adjacent urothelium, COX-2 immunostaining was detected in 22%. COX-2 immunostaining is detected focally in the cytoplasm of umbrella cells of the urothelium adjacent to UCB (Figure 1(a)). Immunostaining was detected in 37.8% of UCB. Diffuse cytoplasmic COX-2 immunostaining in malignant urothelial cells is shown in Figures 1(b)–1(d). The incidence of low COX-2 immunostaining is statistically higher than that of high COX-2 immunostaining in the adjacent urothelium as well as in UCB (\( p \leq 0.001 \)). However, COX-2 immunostaining is more reported in UCB than

![Figure 1: COX-2 immunostaining. (a) A section from a normal urinary bladder mucosa shows low COX-2 immunostaining in the apical portion of umbrella cells (200x). (b) A section from a papillary UCB, (c) a section from an invasive UCB, and (d) a section from high-grade UCB. Cytoplasmic COX-2 immunostaining is higher in invasive and high-grade UCB (100x). Immunohistochemistry was done using an anti-COX-2 antibody, diaminobenzidine as the chromogen, and haematoxylin as a counterstain.](image)

| Table 2: Categories of COX-2 immunostaining in UCB and normal urothelium. |
|---------------------------------------------------------------|
| **Primary tumor** | **Normal urothelium** | **p value** |
| \( n = 123 \) | \( n = 25 \) |
| Low immunostaining | 102 (82.9%) | 25 (100%) | 0.033** |
| High immunostaining | 21 (17.1%) | 0 (0%) | <0.001* |

*One sample of the nonparametric chi-squared test; **Mann-Whitney \( U \) test.
in the adjacent urothelium ($p = 0.033$). Data is shown in Table 2.

### 3.2. Correlation of COX-2 Immunostaining with Prognostic Factors of UCB.

The distribution of COX-2 immunostaining among clinicopathological parameters is shown in Table 3. High COX-2 immunostaining is statistically associated with tumors with high grade ($p = 0.013$), tumors associated with distant metastasis ($p = 0.031$), and tumors with positive lymphovascular invasion ($p = 0.008$). High COX-2 immunostaining is associated with the invasiveness of UCB. This is shown as statistically positive association with positive muscle invasion ($p = 0.017$), tumors with high pathological T (pT2 and above) ($p = 0.003$), and high anatomical stages (stage II and above). High COX-2 immunostaining has a borderline statistically significant association with positive lymph node metastasis ($p = 0.08$). There is no statistically significant difference in COX-2 immunostaining in relation to age groups, sex, local disease recurrence, and survival status. Regression analysis revealed that high COX-2 immunostaining is an independent predictor of higher tumor grade ($p < 0.001$), muscle invasion ($p = 0.015$), advanced pathological T ($p = 0.014$), lymphovascular invasion ($p = 0.011$), and distant metastasis ($p = 0.039$). Details of regression analysis are shown in Table 4.

### 3.3. Survival Outcome in relation to COX-2 Immunostaining.

The survival analysis revealed that there is a statistically significant lower overall survival rate in patients with high COX-2 immunostaining than in patients with low COX-2

---

### Table 3: Correlation between COX-2 immunostaining and clinicopathological features of UCB.

| Parameter                  | COX-2 immunostaining |       |   |
|----------------------------|----------------------|-------|---|
|                            | Low                  | High  |   |
| Sex                        | Male                 | 85    | 17|
|                            | Female               | 17    | 4 |
| Age                        | <60 years            | 41    | 6 |
|                            | ≥60 years            | 61    | 15|
| Grade                      | Low grade            | 30    | 1 |
|                            | High grade           | 72    | 20|
| Muscle invasion            | Negative             | 40    | 2 |
|                            | Positive             | 58    | 19|
|                            | Indeterminate        | 4     | 0 |
| Pathological stage (pT)    | pT1                  | 44    | 2 |
|                            | pT2                  | 58    | 19|
|                            | pT3                  |       |   |
|                            | pT4                  |       |   |
| Nodal metastasis           | Negative             | 85    | 13|
|                            | Positive             | 17    | 8 |
| Distant metastasis         | Negative             | 100   | 10|
|                            | Positive             | 2     | 11|
| Lymphovascular invasion    | Negative             | 97    | 4 |
|                            | Positive             | 5     | 17|
| Anatomical stage           | I                    | 41    | 2 |
|                            | II                   | 61    | 19|
|                            | III                  |       |   |
|                            | IV                   |       |   |
| Local disease recurrence   | Negative             | 69    | 14|
|                            | Positive             | 33    | 7 |
| Survival                   | Alive                | 71    | 16|
|                            | Dead                 | 31    | 5 |

*Kruskal-Wallis test; *Mann-Whitney U test; T1: tumor invades subepithelial connective tissue; T2: tumor invades muscularis propria; T3: tumor invades perivesical tissue; T4: tumor invades any of the following: prostatic stroma, seminal vesicles, uterus, vagina, pelvic wall, or abdominal wall; stage I: T1, N0, and M0; stage II: T2, N0, and M0; stage III: T3 or T4a, N0, and M0; stage IV: any T and N1-3 or M1.

### Table 4: Regression analysis for COX-2 immunostaining in UCB.

| Variable          | Exp($\beta$) | 95% CI for exp($\beta$) | p value |
|-------------------|--------------|-------------------------|---------|
| Grade             | 2.4          | 1.568-3.674              | <0.001  |
| Muscle invasion   | 0.153        | 0.034-0.692              | 0.015   |
| Pathological stage (pT) | 0.150 | 0.033-0.680              | 0.014   |
| Lymphovascular invasion | 0.259 | 0.091-0.736              | 0.011   |
| Distant metastasis | 0.272        | 0.079-0.938              | 0.039   |

---
immunostaining (log-rank (Mantel-Cox) = 5.485 and \( p = 0.019 \)) (Figure 2). Even though disease-free survival is not statistically significant (log-rank (Mantel-Cox) = 2.325, \( p = 0.127 \)), there is a clear trend that patients with tumors with low COX-2 immunostaining have longer disease-free survival and those with tumors with high COX-2 immunostaining have shorter disease-free survival (Figure 3).

4. Discussion

COX-2 is not usually expressed in tissues; however, it is induced under certain stimuli including inflammatory cytokines, growth factors, and oncogenes [24]. Increased immunostaining of COX-2 is observed in different tumors including UCB [11, 13]. However, in the normal human urinary bladder epithelium, COX-2 is not expressed [13, 20, 24–26]. On the other hand, other studies demonstrated weak COX-2 immunoreactivity in the urothelium of normal bladder tissue [27]. In the present study, tissues from the morphological normal urothelium adjacent to UCB were examined for COX-2 immunostaining. In the examined specimens, COX-2 showed low immunostaining (<10%) by apical localisation. This observation was previously reported and consistent with our finding [13, 20]. This observation may represent a field effect of carcinogens in urine on urothelial cells surrounding tumors [29]. This issue is very important and needs to be addressed on large-scale samples as it may be useful to use COX-2 inhibitors as chemopreventive for local tumor recurrence.

COX-2 overexpression may be involved in initiating carcinogenesis [30, 31]. In the present study, high COX-2 immunostaining is statistically higher in UCB than in the adjacent urothelium. High immunostaining was reported in 17.1% of UCB. 10% of immunoreactive cells were used as the cut-off point which was previously used and showed similar results regarding COX-2-positive immunostaining in UCB [22, 24, 32]. However, others reported COX-2 immunostaining in a large number of UCB [13, 21, 33]. Difference in COX-2 immunostaining between normal and tumor tissues may be explained by paracrine effects between normal and tumor tissues. The discrepant results may be due to different technical conditions in COX-2 immunostaining and different interpretation of COX-2 immunostaining.

Most of the well-known prognostic markers of tumors are clinical and pathological parameters including the stage and grade. On the other hand, the assessment of the biological behaviour of tumors is essential to set the appropriate therapeutic modality. So, more reliable prognostic factors are needed. The current approach is to focus on genetic markers [34]. One of the molecules targeted in this process is COX-2 which is considered a risk factor for development and invasion of urinary bladder carcinoma [35]. There are still contradictory results regarding COX-2 expression as an independent prognostic factor of UCB. The association between COX-2 and clinicopathological parameters is a
contentious issue. In our study, high COX-2 immunostaining is associated with advanced tumor stages. There are several studies reporting the same association [28, 32, 36]. On the other hand, other studies failed to show association between COX-2 expression and grade in UCB [20, 22, 24, 29, 37, 38]. It was reported that COX-2 helps the invasive ability on malignant cells in vitro and may be involved in UCB carcinogenesis [24, 30, 39]. The results from our study showed that high COX-2 immunostaining is associated with the invasiveness of UCB. This is expressed by positive association with muscle invasion, high pathological T (pT2 and above), and high anatomical stages (stage II and above). Similar previous findings were reported in previous studies [11, 32, 40]. But there are some other studies which failed to prove such association [29, 36]. Also, we reported that high COX-2 immunostaining is statistically associated with tumors with positive lymphovascular invasion similar to that of a previous report [36]. These findings may support the potential role of COX-2 inhibitors in invasive UCB.

Our study showed that high COX-2 immunostaining has a borderline statistically significant association with positive lymph node metastasis and tumors are associated with distant metastasis (p = 0.031). There are few studies that involved COX-2 immunostaining association with the metastatic potential of UCB. One study noted a significant correlation between COX-2 immunostaining and nodal metastasis [37]. On the other hand, another study did not show a significant correlation with lymph node metastasis [29].

In the current study, regression analysis revealed that high COX-2 immunostaining is an independent predictor of higher tumor grade, muscle invasion, advanced pathological T, lymphovascular invasion, and distant metastasis. A previous study reported that COX-2 correlated significantly with local invasion [24]. High COX-2 immunostaining may be used as an independent predictor of poor UCB outcome. Some suggested that the COX-2 expression may be associated with tumors of good prognosis [41]. However, in this study, the staining intensity was used to assess COX-2 immunostaining. In our study, high COX-2 immunostaining was associated with overall survival. However, there was no association with disease-free survival, a finding that had been reported previously [32], contrary to some previous studies that reported that high COX-2 immunostaining is associated with disease-specific survival [38, 41]. To sum up, the above-mentioned contradictions in results of COX-2 immunostaining in UCB may be referred to as differences in sample sizes, cutoff points of COX-2 immunostaining, antibody clones, and immunostaining techniques.

5. Conclusion

In conclusion, the current study states that COX-2 immunostaining is associated with the invasiveness of UCB and supports that COX-2 immunostaining may be used as an independent prognostic biological marker in UCB. COX-2 may be a significant molecule in the initiation and progression of UCB. Subsequently, COX-2 inhibitors may be used as preventive and therapeutic agents in UCB. Molecular investigations and clinical trials are required to explore the molecular association of COX-2 expression with the development of UCB and effectiveness of COX-2 inhibitors as adjuvant therapy along with traditional chemotherapy.

Abbreviations

COX-2: Cyclooxygenase-2
UCB: Urothelial carcinoma of the urinary bladder.

Data Availability

No data were used to support this study.

Ethical Approval

The Research Committee of the Biomedical Ethics Unit, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, approved this study.

Consent

Informed written consents to use their biopsy material in research were obtained from patients included in this study.

Disclosure

The abstract was presented in the USCAP 2018 107th annual meeting: Genitourinary Pathology (number: 987, pages: 323-324).

Conflicts of Interest

The authors confirm that no part of this work has been submitted or published elsewhere and that there are no conflicts of interest.

Authors’ Contributions

BM shared in the scoring of COX-2 immunostaining and revised the manuscript. WG shared in the tissue microarray design and the scoring of COX-2 immunostaining, performed the statistical analysis, and drafted and revised the manuscript. MA did the scoring of immunostaining and revised the manuscript. JM shared in the histological examination and selection of paraffin blocks, contributed to the design of the study, and revised the manuscript. The manuscript has been read and approved by all of the authors, the requirements for authorship have been met, and each author believes that the manuscript represents honest work.

Acknowledgments

The authors acknowledge with thanks the National Plan for Science, Technology and Innovation (MAARIF-AH), King Abdulaziz City for Science and Technology, the Kingdom of Saudi Arabia, and also the Science and Technology Unit, King Abdulaziz University, for the technical support.
References

[1] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011.

[2] S. Bazarbashi, H. Al Eid, and J. Minguet, “Cancer Incidence in Saudi Arabia: 2012 Data from the Saudi Cancer Registry,” Asian Pacific journal of cancer prevention: APICP, vol. 18, no. 9, p. 2437, 2017.

[3] X. R. Wu, “Urothelial tumorigenesis: a tale of divergent pathways,” Nature Reviews Cancer, vol. 5, no. 9, pp. 713–725, 2005.

[4] M. F. Botteman, C. L. Pashos, A. Redaelli, B. Laskin, and R. Hauser, “The health economics of bladder cancer: a comprehensive review of the published literature,” Pharmacoeconomics, vol. 21, no. 18, pp. 1315–1330, 2003.

[5] D. S. Michaud, “Chronic inflammation and bladder cancer,” Urologic Oncology, vol. 25, no. 3, pp. 260–268, 2007.

[6] R. E. Harris, “Cyclooxygenase-2 (cox-2) and the inflammogenecis of cancer,” Sub-Cellular Biochemistry, vol. 42, pp. 93–126, 2007.

[7] J. Fortuny, M. Kogevinas, M. Garcia-Closas et al., “Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain,” Cancer Epidemiology Biomarkers & Prevention, vol. 15, no. 9, pp. 1696–1702, 2006.

[8] A. Greenough, H. J. M. Smartt, A. E. Moore et al., “The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment,” Carcinogenesis, vol. 30, no. 3, pp. 377–386, 2009.

[9] M. Tsuji, S. Kawano, S. Tsuji, H. Sawaoka, M. Hori, and R. N. DussBois, “Cyclooxygenase regulates angiogenesis induced by colon cancer cells,” Cell, vol. 93, no. 5, pp. 705–716, 1998.

[10] M. A. Wheeler, D. A. Hausladen, J. H. Yoon, and R. M. Weiss, “Prostaglandin E2 production and cyclooxygenase-2 induction in human urinary tract infections and bladder cancer,” The Journal of Urology, vol. 168, 4, Part 1, pp. 1568–1573, 2002.

[11] T. Shirahama, “Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder,” Clinical Cancer Research, vol. 6, no. 6, pp. 2424–2430, 2000.

[12] S. Hara, Y. Kondo, I. Matsuzawa et al., “Expression of cyclooxygenase-2 in human bladder and renal cell carcinoma,” Advances in Experimental Medicine and Biology, vol. 507, pp. 123–126, 2002.

[13] S. I. Mohammed, D. W. Knapp, D. G. Bostwick et al., “Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder,” Cancer Research, vol. 59, no. 22, pp. 5647–5650, 1999.

[14] C. J. Sweeney, M. S. Marshall, D. S. Barnard et al., “Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue,” Cancer Detection and Prevention, vol. 26, no. 3, pp. 238–244, 2002.

[15] J. Al-Maghribi, A. Buhmeida, E. Emam et al., “Cyclooxygenase-2 expression as a predictor of outcome in colorectal carcino,” World Journal of Gastroenterology, vol. 18, no. 15, pp. 1793–1799, 2012.

[16] C. C. Compton, D. R. Byrd, J. Garcia-Aguilar, S. H. Kurtzman, A. Olawaiye, and M. K. Washington, Eds., AJCC Cancer Staging Atlas, Springer, Second edition, 2012.

[17] H. Moch, P. Humphrey, T. Ulbright, and V. Reuter, WHO Classification of Tumours of the Urinary System and Male Genital Organs, International Agency for Research on Cancer, Lyon, France, 2016.

[18] J. Al-Maghribi, E. Emam, W. Gomaa et al., “c-MET immunostaining in colorectal carcinoma is associated with local disease recurrence,” BMC Cancer, vol. 15, no. 1, p. 676, 2015.

[19] W. Gomaa, Y. Ke, H. Fujii, and T. Helliwell, “Tissue microarray of head and neck squamous carcinoma: validation of the methodology for the study of cutaneous fatty acid-binding protein, vascular endothelial growth factor, involucrin and Ki-67,” Virchows Archiv, vol. 447, no. 4, pp. 701–709, 2005.

[20] V. Margulis, S. F. Shariat, R. Ashfaq et al., “Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder,” The Journal of Urology, vol. 177, no. 3, pp. 1163–1168, 2007.

[21] K. Diamantopoulos, L. Lazaris, E. Mylona et al., “Cyclooxygenase-2 protein expression in relation to apoptotic potential and its prognostic significance in bladder urothelial carcinoma,” Anticancer Research, vol. 25, no. 6C, pp. 4543–4549, 2005.

[22] A. Ristimaki, O. Nieminen, K. Saukkonen, K. Hotakainen, S. Nordling, and C. Haglund, “Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder,” The American Journal of Pathology, vol. 158, no. 3, pp. 849–853, 2001.

[23] H. L. Ke, H. P. Tu, H. H. Lin et al., “Cyclooxygenase-2 (COX-2) up-regulation is a prognostic marker for poor clinical outcome of upper tract urothelial cancer,” Anticancer Research, vol. 32, no. 9, pp. 4111–4116, 2012.

[24] T. Shirahama, T. Morikawa, K. Akiba, and C. Sakakura, “Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder,” Cancer, vol. 92, no. 1, pp. 188–193, 2001.

[25] P. Wadhwa, A. K. Goswami, K. Joshi, and S. K. Sharma, “Cyclooxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder,” International Urology and Nephrology, vol. 37, no. 1, pp. 47–53, 2005.

[26] R. Yoshimura, H. Sano, M. Mitsuhashi, M. Kohno, J. Chargui, and S. Wada, “Expression of cyclooxygenase-2 in patients with bladder carcinoma,” The Journal of Urology, vol. 165, no. 5, pp. 1468–1472, 2001.

[27] M. Moussa, Z. Omran, M. Nesseir, A. Lotfy, and T. Swellam, “Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma,” APMIS, vol. 117, no. 1, pp. 45–52, 2009.

[28] O. A. Hammam, A. A. Aziz, M. S. Rosshdy, and A. M. Abdel Hadi, “Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer,” Medscape Journal of Medicine, vol. 10, no. 3, pp. 60, 2008.

[29] Y. Yamada, K. Nakamura, Y. Inoue et al., “Cyclooxygenase-2 expression in invasive transitional cell carcinoma of the urinary bladder,” Molecular Medicine Reports, vol. 1, no. 6, pp. 791–795, 2008.

[30] S. I. Kim, S. M. Kwon, Y. S. Kim, and S. J. Hong, “Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer,” Urology, vol. 60, no. 5, pp. 816–821, 2002.

[31] S. Oku, M. Higashi, Y. Imazono et al., “Overexpression of cyclooxygenase-2 in high-grade human transitional cell
carcinoma of the upper urinary tract,” *BJU International*, vol. 91, no. 1, pp. 109–114, 2003.

[32] M. J. Czachorowski, A. F. S. Amaral, S. Montes-Moreno et al., “Cyclooxygenase-2 expression in bladder cancer and patient prognosis: results from a large clinical cohort and meta-analysis,” *PLoS One*, vol. 7, no. 9, article e45025, 2012.

[33] W. T. Chen, W. C. Hung, W. Y. Kang et al., “Overexpression of cyclooxygenase-2 in urothelial carcinoma in conjunction with tumor-associated-macrophage infiltration, hypoxia-inducible factor-1α expression, and tumor angiogenesis,” *APMIS*, vol. 117, no. 3, pp. 176–184, 2009.

[34] C. A. Reznikoff, S. Sarkar, K. P. Julicher et al., “Genetic alterations and biological pathways in human bladder cancer pathogenesis,” *Urologic Oncology*, vol. 5, no. 5, pp. 191–203, 2000.

[35] R. Gangwar, A. Mandhani, and R. D. Mittal, “Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North India,” *Surgery*, vol. 149, no. 1, pp. 126–134, 2011.

[36] H. M. Tabriz, G. Olfati, S. A. Ahmadi, and S. Yusefnia, “Cyclooxygenase-2 expression in urinary bladder transitional cell carcinoma and its association with clinicopathological characteristics,” *Asian Pacific Journal of Cancer Prevention*, vol. 14, no. 8, pp. 4539–4543, 2013.

[37] K. Naruse, Y. Yamada, K. Nakamura et al., “Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder,” *Oncology Reports*, vol. 23, no. 6, pp. 1577–1583, 2010.

[38] C. Wulfing, E. Eltze, D. Von Struensee et al., “Cyclooxygenase-2 expression in bladder cancer: tumor-biological and clinical implications,” *Aktuelle Urol*, vol. 35, no. 4, pp. 331–338, 2004.

[39] P. Eschwège, S. Ferlicot, S. Droupy et al., “A histopathologic investigation of PGE2 pathways as predictors of proliferation and invasion in urothelial carcinomas of the bladder,” *European Urology*, vol. 44, no. 4, pp. 435–441, 2003.

[40] S. Gurocak, S. Sozen, O. Erdem et al., “Relation between cyclooxygenase-2 expression and clinicopathologic parameters with patient prognosis in transitional cell carcinoma of the bladder,” *Urologia Internationalis*, vol. 76, no. 1, pp. 51–56, 2006.

[41] A. Aziz, A. Lessard, K. Moore et al., “Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2,” *BJU International*, vol. 108, no. 4, pp. 531–537, 2011.